Taking chemotherapy directly to skin lesions, with Dr Raza Bokhari, Medicus Pharma

For patients with advanced basal cell carcinoma, treatment options are extremely limited. And the surgical option that is available to them, Mohs surgery, can only be performed by about 5,000 surgeons worldwide. But, if it clears its remaining trials and secures regulatory clearance, a new treatment could alleviate that bottleneck by bringing chemotherapy directly to the site of the lesion.

At BIO 2025 in Boston, editor-in-chief Jonah Comstock spoke with Dr Raza Bokhari, CEO of Medicus Pharma, about Skinjet, a novel noninvasive treatment alternative for basal carcinoma of the skin.

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to the source of the lesion, they expect to be able to prevent the need for Mohs surgery in at least 60% of patients and improve their prognosis with earlier treatment.

Bokhari also talks about a few other things Medicus has in its pipeline and reflects on the importance of the BIO conference. Check it all out below – and don’t forget to check out all our BIO 2025 coverage on our BIO Spotlight Page.